Member Info for grizzlyb

Hopefully just simplifying the structure.

Very bare, not even a 'Contact Us'.

Just checked companies house:

Reneuron (UK) Ltd.: 30/05/25 - Application to strike the company off the register

Reneuron Holdings Ltd.: 03/06/25 - First Gazette notice for compulsory strike-off

No change to Group and Limited.

'Re-launch as a Private company focused on its stem cell line development expertise'

“Finally, as the Company is no longer a publicly listed company, I confirm our intention is to work closely with our existing shareholders to determine the best outcome for them including exploring options to allow shareholders to trade shares privately. Further details will be communicated in due course.”

6-monthly.

I was in the vicinity on Friday so had a drive-by. Can confirm no sign of life in the building, no vehicles in the car park. Only some exterior lights left on.

I tried to buy on HL yesterday - at least it's not just me I guess. Do you know the issue? I've held previously with no problem.

Https://find-and-update.company-information.service.gov.uk/company/03375897/filing-history

Exactly, they've been at it for years and have failed miserably. All those alleged value inflection points and value-generating data and sod all to show for it.

The was a statement in the annual review to say cash could run out in February '24 if anticipated inflows did not materialise. They need £7 million just to keep afloat for 12 months, I can't imagine any single partner having the confidence to contribute that much to a business valued at £2 million .

I say more likely, but I guess they have spunked a fair bit to get to this point.

More likely they have retained capital to cover redundancies and creditors rather than spunking the whole lot.

Iain Ross also said in one of these online business updates that they aren't going to run out of cash. A statement of fact, until you read the small print. Did similar happen with RedX? The name alone being a warning sign if ever there was one! Lol.

The annual report can be taken as fact and shouldn't be ignored, I can speculate based on the facts as I wish:

'...there is no guarantee that attempts to secure adequate cash inflows from the Group’s exosome platform, IP and legacy assets or through equity fund raising with the timescales stated above will be successful. These conditions indicate the existence of a material uncertainty, which may cast significant doubt about the Group’s and Company’s ability to continue as a going concern.'

Of course for private investors the hope would be that the CEO and board are working to secure a superb deal for our benefit, but there are no facts suggest this.

That's old news with with no recent feedback - exactly my point.

Read the accounts - 'the Group and Company and have prepared a further plausible but downside scenario which excludes these inflows and indicates a cash runway until February 2024.'

Well guess what, it's February 2024 and there have been no inflows. Indeed, we have no indication that any inflows are forthcoming within the required timeframe. Further, we have no indication of any activity whatsoever from the CEO to justify the outflows.

So again, I am lead to believe their plan is indeed to run out of cash, take private at minimal cost, and then become successful as a private entity.

Irrelevant if they have 4 weeks' cash and don't make any positive announcements within that time.

I've not seen any direction from the company regarding what they plan to achieve before running out of cash, which leads me to believe their plan is indeed to run out of cash, take private at minimal cost, and then become successful as a private entity.

Presumably the company could run out of cash, be taken private by the directors, and then sold on. So yes, a deal could be done at the lowest possible share price. But not in the interests of the current shareholders!

In fact; 'The Directors recognise that not all of these assumed inflows are fully within the control of the Group and Company and have prepared a further plausible but downside scenario which excludes these inflows and indicates a cash runway until February 2024.'

Considering there have been minimal cash inflows, the above scenario is therefore likely and only 4 weeks away. 4 weeks is not long enough to raise sufficient capital to continue operating through issuance of new stock, therefore one might be lead to believe a deal is close.

New Year's resolution is to be more positive about ReNeuron. I'm going for a buyout by GSK, £500 mil.

Seems major pharma have an interest in the field:

https://exosome-rna.com/featured-exosome-job-sr-scientist-exosomes/

You could assume deals are a given, as we're told the trials that have produced the positive data have been funded by the entities that ReNeuron would be partnering with.